nach oben

18.04.2024 | Diabetes and Cardiovascular Disease (D Bruemmer, Section Editor)

Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?

verfasst von: Sivaram Neppala, Jemema Rajan, Eric Yang, Ralph A. DeFronzo

Erschienen in: Current Cardiology Reports

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

What is new? Cardiovascular disease (CVD) is the leading cause of mortality in type 2 diabetes (T2D) individuals. Of the major risk factors for CVD, less than 10% of T2D people meet the American Diabetes Association/American Heart Association recommended goals of therapy. The present review examines how much of the absolute cardiovascular (CV) risk in type 2 diabetes patients can be explained by major CV intervention trials.

Recent Findings

Multiple long-term cardiovascular (CV) intervention trials have examined the effect of specific target-directed therapies on the MACE endpoint. Only one prospective study, STENO-2, has employed a multifactorial intervention comparing intensified versus conventional treatment of modifiable risk factors in T2D patients, and demonstrated a 20% absolute CV risk reduction.

Summary

If the absolute CV risk reduction in these trials is added to that in the only prospective multifactorial intervention trial (STENO-2), the unexplained CV risk is 44.1%.

What are the clinical implications?

Potential explanations for the unaccounted-for reduction in absolute CV risk in type 2 diabetes (T2D) patients are discussed.
Hypothesis: failure to take into account synergistic interactions between major cardiovascular risk factors is responsible for the unexplained CV risk in T2D patients.
Simultaneous treatment of all major CV risk factors to recommended AHA/ADA guideline goals is required to achieve the maximum reduction in CV risk.

Nur mit Berechtigung zugänglich

Centers for Disease Control and Prevention. National diabetes statistics report, 2020: estimates of diabetes and its burden in the United States. (2020). Accessed 30 Nov 2023. https://www.cdc.gov/diabetes/data/statistics-report/index.html

Cheng YJ, et al. Trends and disparities in cardiovascular mortality among U.S. Adults with and without self-reported diabetes, 1988–2015. Diabetes Care. 2018;41:2306–15. https://doi.org/10.2337/dc18-0831(2018).CrossRefPubMed

Virani SS, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation. 2020;141:e139–596. https://doi.org/10.1161/CIR.0000000000000757.CrossRefPubMed

Rawshani A, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633–44. https://doi.org/10.1056/NEJMoa1800256.CrossRefPubMed

Rawshani A, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407–18. https://doi.org/10.1056/NEJMoa1608664.CrossRefPubMed

Centers for Disease Control and Prevention. Chronic kidney disease surveillance system-United States. https://nccd.cdc.gov/CKD/. Assessed 4 Feb 2024.

Kidney Disease: Improving Global Outcomes Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;98:S1–115.

Saran R, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69:A7–8. https://doi.org/10.1053/j.ajkd.2016.12.004.CrossRefPubMedPubMedCentral

Fox CS, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73. https://doi.org/10.1016/S0140-6736(12)61350-6.CrossRefPubMedPubMedCentral

10.

Dalrymple LS, et al. Chronic kidney disease and the risk of end-stage renal disease versus death. J Gen Intern Med. 2011;26:379–85. https://doi.org/10.1007/s11606-010-1511-x.CrossRefPubMed

11.

Andary R, Fan W, Wong ND. Control of cardiovascular risk factors among us adults with type 2 diabetes with and without cardiovascular disease. Am J Cardiol. 2019;124:522–7. https://doi.org/10.1016/j.amjcard.2019.05.035.CrossRefPubMed

12.

•• Gaede P, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59:2298–307. https://doi.org/10.1007/s00125-016-4065-6. STENO-2 is the only large prospective multifactorial intervention study comparing intensified versus conventional treatment of modifiable risk factors in patients with type 2 diabetes. The absolute risk reduction in the intensive versus conventionally treated group was 20%.CrossRefPubMedPubMedCentral

13.

Gaede P, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93. https://doi.org/10.1056/NEJMoa021778.CrossRefPubMed

14.

Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310:356–60. https://doi.org/10.1056/NEJM198402093100605.CrossRefPubMed

15.

Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS, American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Clinical Cardiology; and Council on Hypertension. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022;145:e722–59. https://doi.org/10.1161/CIR.0000000000001040.CrossRefPubMed

16.

ElSayed NA, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care. 2023;46:S158–90. https://doi.org/10.2337/dc23-S010.CrossRefPubMed

17.

Group SR, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16. https://doi.org/10.1056/NEJMoa1511939.CrossRef

18.

Xie X, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–43. https://doi.org/10.1016/S0140-6736(15)00805-3.CrossRefPubMed

19.

Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71:e127–248. https://doi.org/10.1016/j.jacc.2017.11.006.CrossRefPubMed

20.

Group AS, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85. https://doi.org/10.1056/NEJMoa1001286.CrossRef

21.

Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:e285–350. https://doi.org/10.1016/j.jacc.2018.11.003.CrossRefPubMed

22.

Garber AJ, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26:107–39. https://doi.org/10.4158/CS-2019-0472.CrossRefPubMed

23.

Goldberg RB, Stone NJ, Grundy SM. The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guidelines on the management of blood cholesterol in diabetes. Diabetes Care. 2020;43:1673–8. https://doi.org/10.2337/dci19-0036.CrossRefPubMed

24.

Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRefPubMed

25.

Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664.CrossRefPubMed

26.

Keech A, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849–61. https://doi.org/10.1016/S0140-6736(05)67667-2.CrossRefPubMed

27.

Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ. 2014;349:g4379. https://doi.org/10.1136/bmj.g4379.CrossRefPubMedPubMedCentral

28.

O’Donoghue ML, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855–64. https://doi.org/10.1056/NEJMoa2211023.CrossRefPubMed

29.

Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1/4. J Am Coll Cardiol. 2021;77:1564–75. https://doi.org/10.1016/j.jacc.2020.11.079.CrossRefPubMed

30.

Bhatt DL, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22. https://doi.org/10.1056/NEJMoa1812792.CrossRefPubMed

31.

Rossello X, et al. Glycated hemoglobin and subclinical atherosclerosis in people without diabetes. J Am Coll Cardiol. 2021;77:2777–91. https://doi.org/10.1016/j.jacc.2021.03.335.CrossRefPubMed

32.

Bancks MP, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019;42:457–65. https://doi.org/10.2337/dc18-1773.CrossRefPubMedPubMedCentral

33.

Stratton IM, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12. https://doi.org/10.1136/bmj.321.7258.405.CrossRefPubMedPubMedCentral

34.

Raghavan S, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019;8:e011295. https://doi.org/10.1161/JAHA.118.011295.CrossRefPubMedPubMedCentral

35.

• DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia. 2010;53:1270–87. https://doi.org/10.1007/s00125-010-1684-1. Classic review demonstrating that the molecular etiology of the insulin resistance directly promotes atherogenesis in diabetic, as was in nondiabetic individuals.CrossRefPubMedPubMedCentral

36.

Tsao CW, et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation. 2022;145:e153–639. https://doi.org/10.1161/CIR.0000000000001052.CrossRefPubMed

37.

Ford ES, Williamson DF, Liu S. Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol. 1997;146:214–22. https://doi.org/10.1093/oxfordjournals.aje.a009256.CrossRefPubMed

38.

Powell-Wiley TM, et al. Obesity and cardiovascular disease: a scientific statement from the American heart association. Circulation. 2021;143:e984–1010. https://doi.org/10.1161/CIR.0000000000000973.CrossRefPubMedPubMedCentral

39.

Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341:1097–105. https://doi.org/10.1056/NEJM199910073411501.CrossRefPubMed

40.

https://www.niddk.nih.gov/healthstatistics, 2023.

41.

Aminian A, et al. Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity. JAMA. 2019;322:1271–82. https://doi.org/10.1001/jama.2019.14231.CrossRefPubMedPubMedCentral

42.

Doumouras AG, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation. 2021;143:1468–80. https://doi.org/10.1161/CIRCULATIONAHA.120.052386.CrossRefPubMed

43.

• Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023. https://doi.org/10.1056/NEJMoa230756. First study to demonstrate that a GLP-1 receptor agonist decreases the MACE endpoint in obese nondiabetic individuals with preexisting cardiovascular disease.CrossRefPubMed

44.

Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS ONE. 2012;7: e52036. https://doi.org/10.1371/journal.pone.0052036.CrossRefPubMedPubMedCentral

45.

Ferrannini E, et al. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab. 2007;92:2885–92. https://doi.org/10.1210/jc.2007-0334.CrossRefPubMed

46.

DeFronzo RA, Inzucchi S, Abdul-Ghani M, Nissen SE. Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes. Diab Vasc Dis Res. 2019;16:133–43. https://doi.org/10.1177/1479164118825376.CrossRefPubMed

47.

Kernan WN, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31. https://doi.org/10.1056/NEJMoa1506930.CrossRefPubMedPubMedCentral

48.

Lawler PR, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2021;42:113–31. https://doi.org/10.1093/eurheartj/ehaa099.CrossRefPubMed

49.

Tsalamandris S, et al. The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 2019;14:50–9. https://doi.org/10.15420/ecr.2018.33.1.CrossRefPubMedPubMedCentral

50.

Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31. https://doi.org/10.1056/NEJMoa1707914.CrossRefPubMed

51.

Tardif JC, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505. https://doi.org/10.1056/NEJMoa1912388.CrossRefPubMed

52.

Ridker PM, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207. https://doi.org/10.1056/NEJMoa0807646.CrossRefPubMed

53.

Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262:157–72. https://doi.org/10.1111/j.1365-2796.2007.01824.x.CrossRefPubMed

54.

Arora S, et al. Premature ticagrelor discontinuation in secondary prevention of atherosclerotic CVD: JACC review topic of the week. J Am Coll Cardiol. 2019;73:2454–64. https://doi.org/10.1016/j.jacc.2019.03.470.CrossRefPubMed

55.

Bhatt DL, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732–40. https://doi.org/10.1016/j.jacc.2016.03.529.CrossRefPubMed

56.

Cavender MA, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015;131:1047–53. https://doi.org/10.1161/CIRCULATIONAHA.114.013774.CrossRefPubMedPubMedCentral

57.

Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37. https://doi.org/10.1016/j.cmet.2013.04.008.CrossRefPubMed

58.

Sattar N, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9:653–62. https://doi.org/10.1016/S2213-8587(21)00203-5.CrossRefPubMed

59.

Sluik D, et al. Physical Activity and Mortality in Individuals With Diabetes Mellitus: A Prospective Study and Meta-analysis. Arch Intern Med. 2012;172:1285–95. https://doi.org/10.1001/archinternmed.2012.3130.CrossRefPubMed

60.

Riboli E, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5:1113–24. https://doi.org/10.1079/PHN2002394.CrossRefPubMed

61.

Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7:313–24. https://doi.org/10.1016/S2213-8587(18)30154-2.CrossRefPubMed

62.

King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest. 1985;75:1028–36. https://doi.org/10.1172/JCI111764.CrossRefPubMedPubMedCentral

63.

Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes. 2004;53:2735–40. https://doi.org/10.2337/diabetes.53.11.2735.CrossRefPubMed

64.

Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96. https://doi.org/10.1038/nrm1837.CrossRefPubMed

65.

Lazar DF, et al. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. J Biol Chem. 1995;270:20801–7. https://doi.org/10.1074/jbc.270.35.20801.CrossRefPubMed

66.

Coletta DK, et al. Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo. Am J Physiol Endocrinol Metab. 2008;294:E910-917. https://doi.org/10.1152/ajpendo.00607.2007.CrossRefPubMed

67.

Kashyap SR, et al. Insulin resistance is associated with impaired nitric oxide synthase activity in skeletal muscle of type 2 diabetic subjects. J Clin Endocrinol Metab. 2005;90:1100–5. https://doi.org/10.1210/jc.2004-0745.CrossRefPubMed

68.

Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev. 2006;22:423–36. https://doi.org/10.1002/dmrr.634.CrossRefPubMed

69.

Hanley AJ, Williams K, Stern MP, Haffner SM. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio heart study. Diabetes Care. 2002;25:1177–84. https://doi.org/10.2337/diacare.25.7.1177.CrossRefPubMed

70.

Bonora E, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona diabetes complications study. Diabetes Care. 2002;25:1135–41. https://doi.org/10.2337/diacare.25.7.1135.CrossRefPubMed

71.

Howard G, et al. Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) investigators. Circulation. 1996;93:1809–17. https://doi.org/10.1161/01.cir.93.10.1809.CrossRefPubMed

72.

Domanski MJ, et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. J Am Coll Cardiol. 2020;76:1507–16. https://doi.org/10.1016/j.jacc.2020.07.059.CrossRefPubMed

73.

Sattar N, et al. Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation. 2023;147:1872–86. https://doi.org/10.1161/CIRCULATIONAHA.122.063374.CrossRefPubMed

74.

Global Cardiovascular Risk C, et al. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389:1273–85. https://doi.org/10.1056/NEJMoa2206916.CrossRef

75.

Golden SH, et al. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes. 2002;51:3069–76. https://doi.org/10.2337/diabetes.51.10.3069.CrossRefPubMed

76.

Hansson L, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet. 1998;351:1755–62. https://doi.org/10.1016/s0140-6736(98)04311-6.CrossRef

77.

Zoungas S, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371:1392–406. https://doi.org/10.1056/NEJMoa1407963.CrossRefPubMed

78.

Zhang W, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021;385:1268–79. https://doi.org/10.1056/NEJMoa2111437.CrossRefPubMed

79.

Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67. https://doi.org/10.1016/S0140-6736(15)01225-8.CrossRefPubMed

80.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9.

81.

Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med. 1996;335:1001–9. https://doi.org/10.1056/NEJM199610033351401.CrossRefPubMed

82.

Long-Term Intervention with Pravastatin in Ischaemic Disease Study, G. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57. https://doi.org/10.1056/NEJM199811053391902.CrossRef

83.

Heart Protection Study Collaborative, G. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22. https://doi.org/10.1016/S0140-6736(02)09327-3.CrossRef

84.

Sever PS, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58. https://doi.org/10.1016/S0140-6736(03)12948-0.CrossRefPubMed

85.

Cannon CP, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504. https://doi.org/10.1056/NEJMoa040583.CrossRefPubMed

86.

Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85. https://doi.org/10.2337/dc05-2415.CrossRefPubMed

87.

Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland coronary prevention study group. N Engl J Med. 1995;333:1301–7. https://doi.org/10.1056/NEJM199511163332001.CrossRefPubMed

88.

Downs JR, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas coronary atherosclerosis prevention study. JAMA. 1998;279:1615–22. https://doi.org/10.1001/jama.279.20.1615.CrossRefPubMed

89.

Colhoun HM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96. https://doi.org/10.1016/S0140-6736(04)16895-5.CrossRefPubMed

90.

Antithrombotic Trialists C, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–60. https://doi.org/10.1016/S0140-6736(09)60503-1.CrossRef

91.

Group ASC, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;378:1529–39. https://doi.org/10.1056/NEJMoa1804988.CrossRef

92.

Gaziano JM, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392:1036–46. https://doi.org/10.1016/S0140-6736(18)31924-X.CrossRefPubMedPubMedCentral

93.

McNeil JJ, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379:1519–28. https://doi.org/10.1056/NEJMoa1803955.CrossRefPubMedPubMedCentral

94.

Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141.CrossRefPubMed

95.

Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

96.

Husain M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51. https://doi.org/10.1056/NEJMoa1901118.CrossRefPubMed

97.

Holman RR, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228–39. https://doi.org/10.1056/NEJMoa1612917.CrossRefPubMedPubMedCentral

98.

Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.CrossRefPubMed

99.

Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30. https://doi.org/10.1016/S0140-6736(19)31149-3.CrossRefPubMed

100.

Gerstein HC, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896–907. https://doi.org/10.1056/NEJMoa2108269.CrossRefPubMed

101.

Zinman B, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720.CrossRefPubMed

102.

Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925.CrossRefPubMed

103.

Wiviott SD, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389.CrossRefPubMed

104.

Cannon CP, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383:1425–35. https://doi.org/10.1056/NEJMoa2004967.CrossRefPubMed

105.

Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384:129–39. https://doi.org/10.1056/NEJMoa2030186.CrossRefPubMed

Titel: Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?
verfasst von: Sivaram Neppala
Jemema Rajan
Eric Yang
Ralph A. DeFronzo
Publikationsdatum: 18.04.2024
Verlag: Springer US
Erschienen in: Current Cardiology Reports
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI: https://doi.org/10.1007/s11886-024-02055-0

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Unexplained Residual Risk In Type 2 Diabetes: How Big Is The Problem?

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Kardiologie

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

Update Kardiologie